Received Jun 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
schedule recommendations for GARDASIL 9/patient received their first dose at age 11 and their second dose at age 18; No additional AE/No PQC.; This spontaneous report was received from a/an Nurse and refers to a(n) female patient of unknown age. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), (.5 ml), (lot # and expiration date were not reported). The patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), for the treatment of Prophylaxis. HCP called for information regarding alternate dosing schedule recommendations for Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9). HCP stated that a female patient received their first dose at age 11 and their second dose at age 18. No additional patient information available at the time of the call. No symptoms reported at the time of the call. Consent to contact is Yes. No additional AE/No PQC. Lot # is being requested and will be submitted if received.